- Home
- ZIMV vs VALN Comparison
ZIMV vs VALN Comparison
Compare ZIMV & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- VALN
- Stock Information
- Founded
- ZIMV 2021
- VALN 2012
- Country
- ZIMV United States
- VALN France
- Employees
- ZIMV N/A
- VALN N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZIMV Health Care
- VALN Health Care
- Exchange
- ZIMV Nasdaq
- VALN Nasdaq
- Market Cap
- ZIMV 434.5M
- VALN 378.3M
- IPO Year
- ZIMV N/A
- VALN 2021
- Fundamental
- Price
- ZIMV $13.74
- VALN $4.42
- Analyst Decision
- ZIMV Hold
- VALN Strong Buy
- Analyst Count
- ZIMV 3
- VALN 2
- Target Price
- ZIMV $18.33
- VALN $18.50
- AVG Volume (30 Days)
- ZIMV 162.0K
- VALN 25.3K
- Earning Date
- ZIMV 10-30-2024
- VALN 11-07-2024
- Dividend Yield
- ZIMV N/A
- VALN N/A
- EPS Growth
- ZIMV N/A
- VALN N/A
- EPS
- ZIMV N/A
- VALN N/A
- Revenue
- ZIMV $451,294,000.00
- VALN $176,817,979.00
- Revenue This Year
- ZIMV $0.83
- VALN $24.30
- Revenue Next Year
- ZIMV $1.27
- VALN $16.05
- P/E Ratio
- ZIMV N/A
- VALN N/A
- Revenue Growth
- ZIMV 267.15
- VALN N/A
- 52 Week Low
- ZIMV $9.00
- VALN $4.27
- 52 Week High
- ZIMV $22.40
- VALN $11.96
- Technical
- Relative Strength Index (RSI)
- ZIMV 41.74
- VALN 25.94
- Support Level
- ZIMV $13.01
- VALN $4.45
- Resistance Level
- ZIMV $14.76
- VALN $4.73
- Average True Range (ATR)
- ZIMV 0.48
- VALN 0.20
- MACD
- ZIMV 0.01
- VALN -0.07
- Stochastic Oscillator
- ZIMV 28.85
- VALN 9.03
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.